Literature DB >> 17160666

[Sarcomatoid renal cell carcinoma. A rare and aggressive variation of primary renal cell carcinoma].

A Bannowsky1, I Leuschner, H Schiller, K Bothe, D Osmonov, K-P Jünemann, S Hautmann.   

Abstract

Every year, renal cell carcinoma (RCC) is responsible for the highest proportion of cancer-associated deaths in relation to all other malignant urological diseases. Initially called carcinosarcoma, the sarcomatoid differentiation confers higher aggressiveness on any of the different subtypes of RCC, with a frequency of ca. 1%. The presence of a sarcomatoid component makes the disease locally aggressive, which typically presents an advanced grade that is associated with fast progression and fatal outcome in a vast proportion of cases, with median survival lower than 1 year. This is important for predicting the outcome for patients undergoing nephrectomy due to RCC, since chemotherapy in a certain group of patients with progressive disease can be a reasonable alternative to the failure of immunotherapy in sarcomatoid renal carcinoma. We report our experience with sarcomatoid RCC in four patients with extensive tumor progression in comparison to the literature.

Entities:  

Mesh:

Year:  2007        PMID: 17160666     DOI: 10.1007/s00120-006-1249-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  9 in total

1.  Sarcomatoid renal cell carcinoma. A treatable entity.

Authors:  A Sella; C J Logothetis; J Y Ro; D A Swanson; M L Samuels
Journal:  Cancer       Date:  1987-09-15       Impact factor: 6.860

2.  Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. 3.

Authors:  G M Farrow; E G Harrison; D C Utz
Journal:  Cancer       Date:  1968-09       Impact factor: 6.860

3.  Sarcomatoid differentiation in renal cell carcinoma: prognostic implications.

Authors:  Marcos F Dall'Oglio; Marco Lieberknecht; Valter Gouveia; Alexandre C Sant'Anna; Katia R Leite; Miguel Srougi
Journal:  Int Braz J Urol       Date:  2005 Jan-Feb       Impact factor: 1.541

4.  Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.

Authors:  T Cangiano; J Liao; J Naitoh; F Dorey; R Figlin; A Belldegrun
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

5.  Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma.

Authors:  Mohammad H Rashid; Cynthia T Welsh; Nabil K Bissada; Uzair B Chaudhary
Journal:  Am J Clin Oncol       Date:  2005-02       Impact factor: 2.339

6.  Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.

Authors:  John C Cheville; Christine M Lohse; Horst Zincke; Amy L Weaver; Bradley C Leibovich; Igor Frank; Michael L Blute
Journal:  Am J Surg Pathol       Date:  2004-04       Impact factor: 6.394

7.  Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases.

Authors:  J Y Ro; A G Ayala; A Sella; M L Samuels; D A Swanson
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

8.  Stratification of risk factors in renal cell carcinoma.

Authors:  C Selli; W M Hinshaw; B H Woodard; D F Paulson
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

9.  Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.

Authors:  David M Nanus; Alexandria Garino; Matthew I Milowsky; Maureen Larkin; Janice P Dutcher
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

  9 in total
  1 in total

1.  Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.

Authors:  Michael Staehler; N Haseke; A Roosen; T Stadler; M Bader; M Siebels; A Karl; C G Stief
Journal:  Eur J Med Res       Date:  2010       Impact factor: 2.175

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.